Company

Nucleai Inc.

Tel Aviv-based Nucleai develops AI software that uses machine learning to detect cancer and gastrointestinal disease.

About

Based in Tel Aviv, Israel, Nucleai was founded in 2018 by Avi Veidman, Eliron Amir and Lotan Chorev. Its AI-driven spatial biology platform analyzes cellular interactions in biopsies to support precision medicine, drug development and biomarker discovery for pharmaceutical companies. In April 2024 it raised USD 14 million in Series B funding led by Merck Ventures.

4Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in